Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Biomech Model Mechanobiol ; 15(6): 1577-1600, 2016 12.
Artículo en Inglés | MEDLINE | ID: mdl-27037954

RESUMEN

In this work, we develop a mathematical formalism based on a 3D in vitro model that is used to simulate the early stages of angiogenesis. The model treats cells as individual entities that are migrating as a result of chemotaxis and durotaxis. The phenotypes used here are endothelial cells that can be distinguished into stalk and tip (leading) cells. The model takes into account the dynamic interaction and interchange between both phenotypes. Next to the cells, the model takes into account several proteins such as vascular endothelial growth factor, delta-like ligand 4, urokinase plasminogen activator and matrix metalloproteinase, which are computed through the solution of a system of reaction-diffusion equations. The method used in the present study is classified into the hybrid approaches. The present study, implemented in three spatial dimensions, demonstrates the feasibility of the approach that is qualitatively confirmed by experimental results.


Asunto(s)
Modelos Biológicos , Neovascularización Fisiológica , Fenómenos Biomecánicos , Simulación por Computador , Dermis/citología , Células Endoteliales/citología , Células Endoteliales/metabolismo , Fibrina/metabolismo , Análisis de Elementos Finitos , Humanos , Metaloproteinasas de la Matriz/metabolismo , Activador de Plasminógeno de Tipo Uroquinasa/metabolismo , Factor A de Crecimiento Endotelial Vascular/metabolismo
2.
Leukemia ; 29(5): 1133-42, 2015 May.
Artículo en Inglés | MEDLINE | ID: mdl-25371178

RESUMEN

Mutations or deletions in TP53 or ATM are well-known determinants of poor prognosis in chronic lymphocytic leukemia (CLL), but only account for approximately 40% of chemo-resistant patients. Genome-wide sequencing has uncovered novel mutations in the splicing factor sf3b1, that were in part associated with ATM aberrations, suggesting functional synergy. We first performed detailed genetic analyses in a CLL cohort (n=110) containing ATM, SF3B1 and TP53 gene defects. Next, we applied a newly developed multiplex assay for p53/ATM target gene induction and measured apoptotic responses to DNA damage. Interestingly, SF3B1 mutated samples without concurrent ATM and TP53 aberrations (sole SF3B1) displayed partially defective ATM/p53 transcriptional and apoptotic responses to various DNA-damaging regimens. In contrast, NOTCH1 or K/N-RAS mutated CLL displayed normal responses in p53/ATM target gene induction and apoptosis. In sole SF3B1 mutated cases, ATM kinase function remained intact, and γH2AX formation, a marker for DNA damage, was increased at baseline and upon irradiation. Our data demonstrate that single mutations in sf3b1 are associated with increased DNA damage and/or an aberrant response to DNA damage. Together, our observations may offer an explanation for the poor prognosis associated with SF3B1 mutations.


Asunto(s)
Regulación Leucémica de la Expresión Génica , Leucemia Linfocítica Crónica de Células B/genética , Mutación , Fosfoproteínas/genética , Ribonucleoproteína Nuclear Pequeña U2/genética , Apoptosis , Proteínas de la Ataxia Telangiectasia Mutada/metabolismo , Estudios de Cohortes , Daño del ADN , Análisis Mutacional de ADN , Doxorrubicina/farmacología , Citometría de Flujo , Eliminación de Gen , Genoma Humano , Histonas/metabolismo , Humanos , Imidazoles/farmacología , Piperazinas/farmacología , Pronóstico , Factores de Empalme de ARN , Receptor Notch1/genética , Proteína p53 Supresora de Tumor/genética , Vidarabina/análogos & derivados , Vidarabina/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA